FindTrial
Sign In

QL1604

DRUG6 trials

Sponsors

Qilu Pharmaceutical Co., Ltd.

Conditions

Advanced Gastric or Gastroesophageal Junction AdenocarcinomaAdvanced Liver CancerAdvanced Malignant TumorAdvanced Solid TumorCervical CancerSmall-cell Lung Cancer

Phase 1

A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma
NCT05603039
Qilu Pharmaceutical Co., Ltd.Advanced Liver Cancer
Start: 2021-07-01End: 2023-12-30Target: 80Updated: 2022-11-02
A Phase I Study of QL1604 for Advanced Solid Tumors
NCT05801094
Qilu Pharmaceutical Co., Ltd.Advanced Solid Tumor
Start: 2020-07-20End: 2023-12-15Updated: 2023-04-06

Phase 2

QL1604 Monotherapy for dMMR or MSI-H Advanced Solid Tumors
NCT04326829
Qilu Pharmaceutical Co., Ltd.Advanced Malignant Tumor
Start: 2020-07-08End: 2023-07-31Target: 86Updated: 2022-12-07
A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer.
NCT04435652
Qilu Pharmaceutical Co., Ltd.Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Start: 2020-07-01End: 2022-11-30Target: 492Updated: 2020-06-17
QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer
TerminatedNCT04864782
Qilu Pharmaceutical Co., Ltd.Cervical Cancer
Start: 2020-09-23End: 2023-11-01Updated: 2024-01-12

Phase 3

a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy.
Not yet recruitingNCT06789796
Qilu Pharmaceutical Co., Ltd.Small-cell Lung Cancer
Start: 2025-02-28End: 2030-03-31Target: 636Updated: 2025-02-11

Related Papers

First-line iparomlimab and tuvonralimab (QL1706) or iparomlimab (QL1604) + bevacizumab (BEV) for unresectable hepatocellular carcinoma (HCC): Updated results from the phase Ib/II DUBHE-H-106 study.
Journal of Clinical Oncology2025-01-27
Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II trial.
2024-11-114 citations
Efficacy and Safety of Iparomlimab, an Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors: A Phase 1c Study.
2024-09-14
Iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors: A single-arm, multicenter, pivotal, phase II study.
Journal of Clinical Oncology2024-06-011 citations
A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL1604, a humanized anti–PD-1 mAb, in patients with advanced or metastatic solid tumors
Frontiers in Immunology2023-10-233 citations
An open-label, multicenter, adaptive, phase Ib/II study of QL1706 or QL1604 plus bevacizumab as first-line treatment in patients with advanced hepatocellular carcinoma.
Journal of Clinical Oncology2023-06-011 citations